{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-308343","form_type":"8-K","ticker":"DYN","cik":"0001818794","company_name":"Dyne Therapeutics, Inc.","filed_at":"2026-07-20T11:35:14+00:00","discovered_at":"2026-07-20T11:40:00.263894+00:00","generated_at":"2026-07-20T11:40:04.732217+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"FDA accepts Dyne's BLA for DYNE-251 in DMD exon 51 skipping; Priority Review granted","bullets":["FDA accepted BLA for z-rostudirsen (DYNE-251) to treat Duchenne muscular dystrophy amenable to exon 51 skipping.","Priority Review assigned; PDUFA target action date is January 21, 2027.","Company expects potential U.S. launch in Q1 2027 if approved on anticipated timeline."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-308343","json":"https://secwatch.observer/filing/0001193125-26-308343.json","markdown":"https://secwatch.observer/filing/0001193125-26-308343.md","text":"https://secwatch.observer/filing/0001193125-26-308343.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526308343/0001193125-26-308343-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526308343/dyn-20260720.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-20T11:40:04.732217+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}